<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>B cell-activating factor receptor (BAFF-R) is one of three known receptors for BAFF, a critical regulator of B- and T-cell function </plain></SENT>
<SENT sid="1" pm="."><plain>In mice, BAFF-R is required for B-cell maturation and survival, and in mice and humans, the overproduction of BAFF is associated with <z:hpo ids='HP_0002960'>autoimmune disease</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>We sought to determine the <z:mpath ids='MPATH_458'>normal</z:mpath> pattern of BAFF-R expression at specific stages of B- and T-cell development and whether this pattern of expression corresponds with related B- and T-cell <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Most circulating human B cells and a small subset of T cells are BAFF-R-positive </plain></SENT>
<SENT sid="4" pm="."><plain>In reactive lymphoid tissues, BAFF-R is expressed by B cells colonizing the mantle zones, by a subset of cells within germinal centers, and rare cells in the interfollicular T-cell zone </plain></SENT>
<SENT sid="5" pm="."><plain>BAFF-R is also expressed by B cells colonizing the splenic marginal zone </plain></SENT>
<SENT sid="6" pm="."><plain>Seventy-seven (78%) of 116 cases of B-cell <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> were BAFF-R-positive by immunohistochemical and/or flow cytometric immunophenotypic analysis, including most cases of mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, marginal zone <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo>, hairy cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>, and diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>In contrast, cases of precursor B lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and nodular lymphocyte-predominant Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> exhibit weak to negative staining for BAFF-R </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> cases of classical Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and T-cell <z:hpo ids='HP_0002665'>lymphomas</z:hpo> were BAFF-R-negative, including <z:hpo ids='HP_0000001'>all</z:hpo> cases of anaplastic large cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, adult T-cell <z:hpo ids='HP_0001909'>leukemia</z:hpo>/<z:hpo ids='HP_0002665'>lymphoma</z:hpo>, angioimmunoblastic T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, and peripheral T-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, unspecified </plain></SENT>
<SENT sid="9" pm="."><plain>These findings highlight BAFF-R as a marker of both <z:mpath ids='MPATH_458'>normal</z:mpath> and neoplastic B cells and raise the possibility that BAFF-R expression is necessary for the survival of a subset of neoplastic B lymphocytes analogous to its known role in promoting <z:mpath ids='MPATH_458'>normal</z:mpath> B-cell maturation and survival </plain></SENT>
</text></document>